Clinical Trials on Stomach Adenocarcinoma

Total 12683 results

Fujian Cancer Hospital

Unknown

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Marmara University

Not yet recruiting

Gastrectomy Outcomes in Elderly Patients (GOE)

Gastric Cancer | Gastric Adenocarcinoma | Elderly | Gastrectomy

Turkey
National Cancer Institute (NCI)

Recruiting

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

Gastric Cancer | Gastric Adenocarcinoma | Gastric Neoplasms

United States
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
University of Zurich

Withdrawn

Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach

Adenocarcinoma | Stomach Cancer | Cancer of Esophagogastric Junction

Switzerland
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma

Stomach Cancer | Gastric Cancer | Esophageal Cancer

United States
National Cheng-Kung University Hospital
China Medical University Hospital; Taipei Veterans General Hospital, Taiwan; Kaohsiung... and other collaborators

Recruiting

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (LOTS)

Gastric Cancer | Gastric Adenocarcinoma | Toxicity Due to Chemotherapy | Effects of Chemotherapy

Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Gastric Cancer | Gastric Adenocarcinoma | Esophagogastric Junction

United States
Yu jiren

Not yet recruiting

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Epstein-Barr Virus-Associated Gastric Carcinoma

China
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
The First Affiliated Hospital with Nanjing Medical...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma (EXPLORING)

Digestive System Diseases | Gastrointestinal Diseases | Carcinoma | Gastrointestinal Neoplasms | Stomach Cancer | Gastric Cancer | Gastroesophageal-junction Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Clinica Universidad de Navarra, Universidad de...

Completed

Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients

Adenocarcinoma | Gastrointestinal Neoplasms | Gastric Cancer | Surgery | Effects of Chemotherapy

Spain
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
University Hospital, Lille
National Cancer Institute, France

Recruiting

Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer (SURGIGAST)

Gastric Adenocarcinoma

France
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
LianBio LLC

Recruiting

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Hallym University Medical Center

Not yet recruiting

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Genome & Company
Merck KGaA, Darmstadt, Germany

Active, not recruiting

GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Sanofi; University of Pittsburgh; Medical College of Wisconsin; Weill Medical College... and other collaborators

Completed

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Cancer Institute and Hospital, Chinese Academy...

Completed

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital

Completed

Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Gastro-esophageal Junction Cancer

United States
Universidade Federal do Amazonas

Completed

Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer (PRONIC-G)

Gastric Cancer | Nutritional Status | Gastric Adenocarcinoma | Cytokines | Microbiome

Brazil
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Shanghai Cancer Hospital, China
Fudan University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University... and other collaborators

Recruiting

PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy (PREACT)

Adenocarcinoma | Chemoradiation | GastroEsophageal Cancer | Stomach Neoplasm | Locally Advanced Cancer

China
West China Hospital

Recruiting

Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors

Recurrence | Stomach Neoplasms | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric Junction

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

China
Mayo Clinic

Recruiting

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

Gastric Adenocarcinoma | Clinical Stage IV Gastric Cancer AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Gastric Adenocarcinoma | Oligometastasis | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Stage IV Esophageal Adenocarcinoma AJCC v7

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (INTEGA)

Gastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric Cancer

Germany
European Organisation for Research and Treatment...

Terminated

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

Belgium, Portugal, Germany
Fudan University

Unknown

PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Metastatic Gastric Cancer | Locally Advanced Gastric Adenocarcinoma

China
National Cancer Institute (NCI)

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Fox Chase Cancer Center
AstraZeneca

Completed

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Cancer of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Cancer of the Stomach

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer

United States
LianBio LLC

Recruiting

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (FGFR)

Gastric Cancer | Solid Tumor | Gastroesophageal Junction Adenocarcinoma

China
Henan Cancer Hospital

Not yet recruiting

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Federation Francophone de Cancerologie Digestive

Completed

Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

France
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
Qilu Hospital of Shandong University

Not yet recruiting

The Role of Artificial Intelligence in Endoscopic Diagnosis of Esophagogastric Junctional Adenocarcinoma：A Single Center, Case-control, Diagnostic Study

Stomach Neoplasms
Samsung Medical Center

Completed

Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

Stomach Neoplasms

Korea, Republic of
Wuhan Union Hospital, China

Not yet recruiting

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Stomach Neoplasms

China
Sanofi

Completed

Docetaxel in Locally Advanced Gastric Adenocarcinoma (NEOTAX)

Stomach Neoplasms

Turkey
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Stage III Gastric Cancer | Adenocarcinoma of the Stomach | Stage IV Esophageal Cancer | Stage III Esophageal Cancer

Canada, United States

Clinical Trials on Stomach Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations